Delving into the Latest Updates on Mepolizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Bosatria, Mepolizamab, Mepolizumab (Genetical Recombination)

+ [7]

Target

IL-5

Action

inhibitors

Mechanism

IL-5 inhibitors(Interleukin-5 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesCardiovascular Diseases+ [5]

Active Indication

Pulmonary Disease, Chronic ObstructiveAsthmaChronic rhinosinusitis with nasal polyps+ [7]

Inactive Indication

Asthma, Nasal Polyps, and Aspirin IntoleranceDeglutition DisordersEosinophilic Esophagitis+ [5]

Originator Organization

GSK Plc

Active Organization

GSK Plc

GlaxoSmithKline (China) Investment Co., Ltd.GlaxoSmithKline Trading Services Ltd.

+ [4]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (04 Nov 2015),

Severe asthma

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (South Korea), Priority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 42934L

Source: *****

Sequence Code 43483H

Source: *****

The development of coronary atherosclerosis is closely related to inflammation, and CD147 may play an important role in its process. The present study was designed to evaluate the effects of long-term administration of mepolizumab (humanized anti-CD147 antibody) on lipid deposition and inflammation in coronary atherosclerotic plaques in patients with high-risk coronary artery disease, and to preliminarily explore the efficacy, safety, and dosage of long-term administration of mepolizumab in this population.

Start Date16 Oct 2024

Sponsor / Collaborator

Xijing Hospital

NCT06501807

/ Not yet recruitingNot ApplicableIIT

Real Life Assessment of Biologics Efficacy in Severe Chronic Rhinosinusitis With Nasal Polyps

With a prevalence of 2-4% in western countries, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is of major concern regarding its substantial impact on the social and physical quality of life. So far, endoscopic sinus surgery remains the treatment of choice when the first line of medical treatment with corticosteroid has failed.
During the last 15 years, several studies have shown that CRSwNP is associated with a T helper 2 (T2) immune response leading to B cell release of IgE, mucosal recruitment of eosinophils from bone marrow via Interleukin (IL)-5, IL-4 and IL-13 mediated chemoattractant production.
New biologic agents capable of blocking T2 cytokines have been developed in the field of eosinophil-associated diseases, shifting the paradigm of treatment for patients with CRSwNP. In the near future, endotype profiling with accurate biomarkers will be mandatory to tailor the treatment of nasal polyposis with specific biologic therapies.
Herein the investigators propose a prospective study monitoring medical records of CRSwNP patients who undergo biologic treatments. The objectives are to assess treatment efficacy on quality of life, to report clinical and biological criteria for prescription and to measure tolerance and compliance.Patient-reported outcomes will be addressed according to their initial clinical profile (allergy, asthma, NSAID, gastroesophageal reflux disease, obstructive apnea, otologic disorder, smoke habit).

Start Date02 Sep 2024

Sponsor / Collaborator-

100 Clinical Results associated with Mepolizumab

Login to view more data

100 Translational Medicine associated with Mepolizumab

Login to view more data

100 Patents (Medical) associated with Mepolizumab

Login to view more data

1,589

Literatures (Medical) associated with Mepolizumab

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of mepolizumab vs anti-interleukin-5/5r biologic therapies for the treatment of adults with severe asthma with an eosinophilic phenotype: a Chilean healthcare system perspective

Article

Author: Romero, Jose ; Giovini, Vanina ; Espinoza, Manuel Antonio ; Balmaceda, Carlos ; Moraes dos Santos, Felipe ; Rodríguez Martínez, Consuelo

AIM:

Asthma is a heterogeneous respiratory condition often classified into distinct phenotypes. Severe asthma, characterized by uncontrolled symptoms despite optimal treatment, imposes a significant burden on healthcare systems, particularly in low- and middle-income countries. This study evaluates the cost-effectiveness of mepolizumab compared with other interleukin (IL)-5 pathway inhibitors, benralizumab and reslizumab, in treating severe asthma with an eosinophilic phenotype in Chile.

MATERIALS AND METHODS:

A Markov cohort model was developed to compare mepolizumab (100 mg subcutaneously every four weeks) with benralizumab (30 mg subcutaneously every four weeks for the first three doses, every eight weeks subsequently) and reslizumab (3 mg/kg intravenously every four weeks), both as add-on therapies to standard care. Data from the Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA) clinical trial and a network meta-analysis were used. Utility values were extracted using the EuroQoL 5-Dimension questionnaire (EQ-5D-5L) questionnaire. Probabilistic and one-way sensitivity analyses assessed model robustness.

RESULTS:

Mepolizumab demonstrated dominance with probability over 95% when compared with benralizumab and reslizumab. Cost savings ranged from 37,000 United States dollars (USD) to 104,000 USD, with an increase of 0.52 to 0.55 quality-adjusted life years. Mepolizumab was also associated with a lower incidence of exacerbations and asthma-related deaths. Sensitivity analyses confirmed the stability of the model outcomes across key parameters.

LIMITATIONS:

Limitations of the economic model are related to the lack of direct comparisons between mepolizumab and other biologics. Additionally, the absence of data on continuation criteria required estimating relative risks for the overall population.

CONCLUSIONS:

Mepolizumab offers greater efficacy and cost savings compared to benralizumab and reslizumab for eosinophilic asthma, providing essential insights for improving asthma management and informing healthcare policies in Chile.

01 Dec 2025·Current Cardiology Reports

Eosinophilic Myocarditis: A Concise Review

Review

Author: Kahwash, Rami ; Trovato, Vincenzo ; Asada, Ashlee M

Abstract:

Purpose of Review:

Eosinophilic myocarditis (EM) is a rare and heterogeneous form of inflammatory heart disease that can present with a wide range of severity. Current literature is limited to case reports or small case series that outline the evaluation process, disease course, and the nonstandardized treatments trialed. This review aims to concisely summarize the current literature on EM including an update on maintenance therapy for refractory or recurrent disease.

Recent Findings:

In the last several years, several observational studies have reported the clinical benefit of mepolizumab and benralizumab in refractory EM.

Summary:

EM is a complex and heterogenous cause of inflammatory heart disease with a wide range of etiologies and presentations. Treatment of this disease has not been standardized as there are no large scale trials quantifying benefit of any specific therapy regimen. Targeted biologics show promise in observational studies; therefore, prospective studies are needed to quantify this benefit in EM.

01 Dec 2025·CURRENT ALLERGY AND ASTHMA REPORTS

Olfactory Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Effect of Treatment with Emphasis on Biological Therapy

Review

Author: Reitsma, Sietze ; Fokkens, Wytske Johanna ; Otten, Josje Janna

PURPOSE OF REVIEW:

Olfactory dysfunction significantly impacts quality of life that affects a majority of the patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The aim of this review is to explore the impact of various treatment regimens on olfactory dysfunction in patients diagnosed with CRSwNP.

RECENT FINDINGS:

Accurate assessment of olfactory dysfunction remains challenging and should incorporate both psychophysical tests and patient-reported outcomes. Patients with CRSwNP appear capable of reliably evaluating their olfactory function. Standard treatment such as intranasal corticosteroids and surgery have limited capability of restoring the sense of smell. Oral corticosteroids have a far greater potency, albeit short-lived and at the cost of adverse events and side effects. Recent studies on registered biological agents- specifically dupilumab, mepolizumab, and omalizumab- indicate their effectiveness in restoring olfactory function in severe CRSwNP. According to meta-analyses and indirect comparisons, dupilumab shows superiority; however, direct comparative studies are necessary.

130

News (Medical) associated with Mepolizumab

09 Jul 2025

·www.fiercepharma.com

Merck boosts respiratory portfolio with $10B acquisition of Verona and potential COPD blockbuster Ohtuvayre

For the third time in the last five years, Merck has pulled off an acquisition in the $10 to $12 billion range, buying out Verona Pharma and its potential COPD blockbuster Ohtuvayre. Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion for Verona Pharma and its potential blockbuster Ohtuvayre, a first-in-class treatment for chronic obstructive pulmonary disorder (COPD).It is the second-largest deal in biopharma this year, ranking behind Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular, and fits Merck’s pattern of striking every other year with a major transaction.In 2021, Merck spent $11.5 billion for Acceleron and its pulmonary arterial hypertension (PAH) treatment, now known commercially as Winrevair. Then in 2023, the New Jersey company ponied up $10.8 billion for Prometheus and its late-stage bowel disease candidate PRA023.The acquisitions are designed to compensate for the expected loss of patent protection later this decade for cancer superstar Keytruda, which generated $29.5 billion in sales in 2024, accounting for 46% of the company’s revenue.“The sweet spot we see is that $1 to $15-billion range,” Davis said in conference call on Wednesday. “As we’ve also consistently indicated, we’re willing to go beyond that for the right opportunity.”Additionally, Davis said that the company plans to launch roughly 20 “new growth drivers in the coming years, almost all of which have blockbuster potential.” He added that Merck will continue to scout out oncology, immunology and cardiometabolic assets through business development.As for the buyout of Verona, Merck has agreed to pay $107 per share, which is a 23% markup on their price at market close Tuesday and a 39% premium on their 60-day volume-weighted average price. The companies expect the deal to close in the fourth quarter of this year.The FDA approved Ohtuvayre 13 months ago as the first novel inhaled treatment for COPD in more than two decades. The drug can be used as a monotherapy or as an add-on medicine with current steroid therapies. As a selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes, Ohtuvayre combines two properties in one medicine, setting it apart from COPD competitors for its ability to both open the airways of patients and reduce their inflammation.Ohtuvayre is off to a solid launch, generating sales of $71 million in the first quarter of this year, good for 95% growth sequentially. During the three months, 25,000 prescriptions were filled, up from 16,000 in 2024.“Since launching Ohtuvayre in August 2024, we have seen rapid and accelerating uptake in the U.S.,” Verona CEO David Zaccardelli said in a release Wednesday. “We believe Merck’s commercial footprint and industry-leading clinical capabilities will help accelerate the potential of Ohtuvayre to reach more patients living with COPD.” The treatment has not been approved in Europe. Some of that advantageous footprint comes through Merck’s commercialization of Winrevair. Although it is a product for a rare lung disease, many of the physicians who prescribe Winrevair will have patients with COPD.The prescriber base for the disease is 14,500 in the U.S., according to Merck’s human health president Jannie Oosthuizen. Verona reported in April that 5,300 doctors had prescribed Ohtuvayre in the first quarter.“I think our scale brings a good ability to expand fairly rapidly into that broader prescriber base, educate and get Ohtuvayre to be added to existing background therapies, especially in those patients with persistent symptoms,” Oosthuizen said, adding that the company expects the market to grow from $17 billion this year to $27 billion by 2032. Meanwhile, other companies are rushing to the COPD space. After a delay, the FDA in May approved GSK's antibody drug Nucala as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. Amgen and AstraZeneca have hopes for their asthma drug Tezspire as a potential COPD treatment.Last year, Regeneron and Sanofi gained approval for Dupixent to treat COPD exacerbations. The companies also have a second COPD candidate in IL-33 inhibitor itepekimab, which is being tested in two phase 3 trials.

Drug ApprovalAcquisitionPhase 3

09 Jul 2025

·www.fiercepharma.com

Respiratory pharma royalty rally around rural COPD education and support drive

The Lung Association is expanding access to the free Lung Health Navigator program. A who’s who of respiratory disease drug developers has backed the American Lung Association’s push to help chronic obstructive pulmonary disease (COPD) patients in rural communities. Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational campaign. The support will equip the Lung Association to work with rural partners and referral networks, plus local healthcare providers, to deliver services and education to COPD patients.The Lung Association created the campaign for all families across the U.S. affected by COPD, but has paid particular attention to people in rural communities. COPD rates are higher in rural communities than urban areas, the nonprofit said, and patients may lack easy access to hospitals and other resources. To address the health equity challenge, the Lung Association is expanding access to the free Lung Health Navigator program. The program connects COPD patients to licensed healthcare professionals, either via a phone call, online chat or video meeting. Patients receive free, one-to-one support. The Lung Association said it is sharing educational materials to help patients “improve communication with their healthcare provider, better understand available COPD treatments and improve their quality of life.” In parallel, the nonprofit is supporting healthcare providers to improve awareness of COPD therapy options.All of the companies that supported the campaign have COPD therapies. Sanofi and Regeneron received FDA approval for Dupixent in the indication last year. The COPD launch got off to a promising start, but the companies’ IL-33 prospect suffered a phase 3 blow in May. Genentech also has an IL-33 candidate. AstraZeneca’s rival IL-33 prospect failed a phase 2 trial last year but development is continuing.AstraZeneca already sells Breztri Aerosphere, an inhaler that competes with GSK’s Trelegy Ellipta for the COPD market. GSK recently won FDA approval for its IL-5 antibody Nucala in COPD. Nucala became the third biologic approved in COPD after Dupixent and Verona Pharma’s Ohtuvayre. Merck & Co. is reportedly closing in on a $10 billion deal to buy Verona.

Drug ApprovalPhase 3AcquisitionPhase 2

07 Jul 2025

·www.fiercepharma.com

KalVista bounces back from FDA delay with approval for oral rare disease med Ekterly

KalVista blamed last month's approval decision delay on the “heavy workload and limited resources” at the FDA, citing comments it had received from the agency. After facing an unexpected regulatory delay last month, KalVista Pharmaceuticals has leapt into the commercial realm with the FDA approval of its plasma kallikrein inhibitor sebetralstat.The FDA has approved sebetralstat under the brand name Ekterly as a new, oral treatment option for acute attacks of hereditary angioedema (HAE) in adults and children ages 12 years and older, KalVista said in a July 7 press release. The nod came just a few short weeks after the agency missed its June 17 target date originally established for the decision.At the time, KalVista blamed the delay on the “heavy workload and limited resources” at the agency, citing comments it had received from the FDA. The update fueled ongoing concerns from industry watchers that mass firings at the Department of Health and Human Services (HHS) and its constituent health agencies had hamstrung the FDA’s ability to keep its regulatory work on track.Still, with the delay now behind the company, KalVista is pressing forward with plans to launch Ekterly in the U.S. “immediately," the company said in its release. Ekterly represents the small Massachusetts biotech’s first commercially approved product.Ekterly’s green light marks a “defining moment for people living with HAE,” KalVista’s CEO, Ben Palleiko, said in a statement, stressing the drug’s ability to treat HAE attacks “the moment symptoms begin, wherever they are.”HAE is a rare genetic disease that leads to deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein, KalVista explained in its approval announcement. The condition causes painful and debilitating attacks of tissue swelling at various points in the body, which can be life-threatening depending on the area affected, the company noted.Prior to the approval of Ekterly, on-demand treatment for HAE attacks had to be administered via subcutaneous injection or intravenously, which can delay already time-sensitive intervention, the University of California, San Diego’s Marc Riedl, M.D., who served as an investigator on the pivotal trial that secured Ekterly’s approval, explained in KalVista’s release. Though multiple drugs have already been cleared for HAE in the U.S.—both for acute attacks and prophylaxis—the simplified oral dosing of KalVista’s on-demand therapy has the potential to make Ekterly a “foundational treatment” for the disease, the company’s CEO Palleiko said.The FDA gave Ekterly the thumbs up after reviewing data from KalVista’s phase 3 KONFIDENT trial, in which the drug demonstrated swifter symptom relief, reduction in attack severity and attack resolution versus placebo. The drug also appeared well-tolerated and had a safety profile on par with the dummy drug, KalVista said.KalVista built on that body of evidence last fall with data from an open-label extension trial that found Ekterly helped patients treat HAE attacks within a median window of 10 minutes following attack onset. The latest data from that extension study, dubbed KONFIDENT-S, found that patients on Ekterly started experiencing symptom relief in a median of 1.3 hours for attacks involving the larynx or abdomen, and for breakthrough attacks in patients receiving long-term preventative treatment. The FDA has struggled to meet several approval timeline targets this year and, in KalVista's case, the agency's Trump administration-appointed commissioner, Marty Makary, M.D., reportedly jockeyed for KalVista's drug to be rejected. Endpoints News reported about the agency's deliberations last month, citing internal communications at the regulator. An HHS spokesperson told the publication that the assertion Makary sought a Complete Response Letter for KalVista's drug was “totally false and untrue.”Aside from KalVista, Novavax and GSK have also encountered delays at the regulator after their target decision dates came and went without approval verdicts. The FDA has subsequently approved both Novavax's and GSK's respective applications, which covered a protein-based COVID-19 vaccine and a new COPD indication for the antibody blockbuster Nucala.

Drug ApprovalPhase 3Clinical ResultVaccine

100 Deals associated with Mepolizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D04923	Mepolizumab	R03DX09	DB06612

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	United States	GSK Plc	22 May 2025
Asthma	Japan	GlaxoSmithKline KK	25 Mar 2020
Chronic rhinosinusitis with nasal polyps	European Union	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Chronic rhinosinusitis with nasal polyps	Iceland	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Chronic rhinosinusitis with nasal polyps	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Chronic rhinosinusitis with nasal polyps	Norway	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Churg-Strauss Syndrome	European Union	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Churg-Strauss Syndrome	Iceland	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Churg-Strauss Syndrome	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Churg-Strauss Syndrome	Norway	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Eosinophilic Asthma	European Union	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Eosinophilic Asthma	Iceland	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Eosinophilic Asthma	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Eosinophilic Asthma	Norway	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Hypereosinophilic Syndrome	European Union	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Hypereosinophilic Syndrome	Iceland	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Hypereosinophilic Syndrome	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Hypereosinophilic Syndrome	Norway	GlaxoSmithKline Trading Services Ltd.	01 Dec 2015
Severe asthma	United States	GlaxoSmithKline LLC	04 Nov 2015

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Eosinophilia	NDA/BLA	China	GlaxoSmithKline (China) Investment Co., Ltd.	14 Mar 2023
Asthma, Nasal Polyps, and Aspirin Intolerance	Phase 3	China	GSK Plc	22 Apr 2021
Asthma, Nasal Polyps, and Aspirin Intolerance	Phase 3	Japan	GSK Plc	22 Apr 2021
Asthma, Nasal Polyps, and Aspirin Intolerance	Phase 3	Russia	GSK Plc	22 Apr 2021
Eosinophilia	Phase 3	United Kingdom	GSK Plc	07 Sep 2020
Nasal Polyps	Phase 3	United States	GSK Plc	25 May 2017
Nasal Polyps	Phase 3	Argentina	GSK Plc	25 May 2017
Nasal Polyps	Phase 3	Australia	GSK Plc	25 May 2017
Nasal Polyps	Phase 3	Canada	GSK Plc	25 May 2017
Nasal Polyps	Phase 3	Germany	GSK Plc	25 May 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


JPRN-UMIN000045021 (J-Real-Mepo Study, ATS2025)	Not Applicable	Galectin-10 (Gal10) \| TARC \| peripheral blood eosinophil counts	78	Mepolizumab	jbwqlnbxae(syimkvpmcv) = comqpylpnm qgpiiibgds (kftfnndrse ) View more	Positive	16 May 2025
NEST (ATS2025)	Not Applicable	Severe asthma eosinophilic phenotype	306	Mepolizumab 100 mg	zydzjfvsxp(zzjbwqrylr) = msnoojmxkq kdvyzrkqme (lavntgbaoc ) View more	Positive	16 May 2025
				Maintenance OCS (mOCS)	zydzjfvsxp(zzjbwqrylr) = psedrdwtkc kdvyzrkqme (lavntgbaoc ) View more
ATS2025	Not Applicable	Severe asthma	308	Mepolizumab	wwutrtckfz(uikyzkvsgi) = eqjadjwmvd zzqhmxnftj (bzbkwcubna ) View more	Positive	16 May 2025
NCT04765722 (MUCOSA, ATS2025)	Phase 4	Refractory chronic cough sputum eosinophilia	30	Mepolizumab 100 mg	ozepsahbho(siuyrpbzsr): % = 18.6 (95% CI, -23 to 82), P-Value = 0.44	Negative	16 May 2025
				Placebo
NEST (ATS2025)	Not Applicable	Severe asthma eosinophilic phenotype	174	Mepolizumab	seifbgcniv(uqrmhjjzxe): incident rate ratio = 0.26 (95% CI, 0.18 - 0.36)	Positive	16 May 2025
				Previous Biologic Treatments
NCT04276233 (PRISM, CTgov)	Phase 4	Asthma \| Eosinophilic Asthma	100	Mepolizumab	fbvbmrqprt = kbyvyajtld ljornnjkwb (ixutdxrqhp, celcdgyypd - pfbcqyihtb) View more	-	10 Dec 2024
NCT04607005 (MERIT, CTgov)	Phase 3	Asthma, Nasal Polyps, and Aspirin Intolerance \| Nasal Polyps \| Chronic rhinosinusitis with nasal polyps	169	Mepolizumab (Mepolizumab)	wejufokocu(mczzdkqfot) = xgutlnglxj hssmuilqqd (wolwtqzsld, 0.164) View more	-	25 Nov 2024
				placebo (Placebo)	wejufokocu(mczzdkqfot) = jdxfxxyase hssmuilqqd (wolwtqzsld, 0.164) View more
NCT00244686 (Pubmed) Manual	Phase 3	Severe asthma	514	Mepolizumab 100 mg SC (Adults/adolescents (≥12 years of age))	hldxysbcmt(vlaulpiyez) = dlqmpnjwgh rubqjjgtrv (uoywkjwwnp )	Positive	28 Oct 2024
				Mepolizumab 40 mg or 100 mg SC (bodyweight <40 or ≥40 kg, respectively) (Pediatric patients (6-11 years of age))	-
ACAAI2024	Not Applicable	Hypereosinophilic Syndrome \| Churg-Strauss Syndrome interleukin-5	60	Mepolizumab 300 mg	wballwkede(mlpncchnpv) = fgqiauxpwc batayvgawi (mnmxgntkmh )	Positive	24 Oct 2024
				Placebo	wballwkede(mlpncchnpv) = yxqdtpndkq batayvgawi (mnmxgntkmh )
NOVEL TREATMENT REGIMEN WITH MEPOLUZIMAB (ACAAI2024)	Not Applicable	Churg-Strauss Syndrome ANCA-negative	1	Mepoluzimab 100 mg every 4 weeks	kdpbuvrwrh(vdmiglfbkz) = bqrycmjtfn cutwebjtat (frhonmjfnl )	Positive	24 Oct 2024

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data